MVASI

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, Turkey.

Active ingredients

The drug MVASI contains one active pharmaceutical ingredient (API):

1	Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB
	Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
	Read more about Bevacizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FG01	Bevacizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12479T, 12508H
CA	Health Products and Food Branch	02470748, 02470756
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	175-MBE-0121
EE	Ravimiamet	1762657, 1762668
ES	Centro de información online de medicamentos de la AEMPS	1171246001, 1171246002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	484229, 573402
FR	Base de données publique des médicaments	61409314
HK	Department of Health Drug Office	67028, 67029
IL	מִשְׂרַד הַבְּרִיאוּת	8967, 8970
IT	Agenzia del Farmaco	045925017, 045925029
LT	Valstybinė vaistų kontrolės tarnyba	1084945, 1084946
NL	Z-Index G-Standaard, PRK	76910, 76929
NZ	Medicines and Medical Devices Safety Authority	20772, 20773
PL	Rejestru Produktów Leczniczych	100400713
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66673001, W66673002
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862760034, 8699862760041
US	FDA, National Drug Code	55513-206, 55513-207